Abstracts tagged "adverse events and autoimmune diseases"

Abstract Number: 357 • 2018 ACR/ARHP Annual Meeting
Musculoskeletal Immune-Related Adverse Events with Use of Checkpoint Inhibitors in Malignancy: Experience in Sydney, Australia
Abhishikta Dey^1,2, Nicholas Manolios^3,4, Georgina Long^4,5,6, Richard Kefford^3,4,5,7 and Leslie Schrieber^8,9, ¹Pain Medicine, Royal Prince Alfred Hospital, Camperdown, Australia, ²Royal North Shore Hospital, North Sydney, Australia, ³Westmead Hospital, Sydney, Australia, ⁴University of Sydney, Sydney, Australia, ⁵Melanoma Institute Australia, North Sydney, Australia, ⁶Royal North Shore Hospital, St Leonards, Australia, ⁷Macquarie University Hospital, Sydney, Australia, ⁸Royal North Shore Hospital, St Leonards, Sydney, Australia, ⁹Northern Clinical School, University of Sydney, Sydney, Australia
Background/Purpose: The strategy of using monoclonal antibodies to inhibit checkpoints on T cells, and enhance T-cell activity against cancer cells has significantly improved the survival…
Abstract Number: 1339 • 2016 ACR/ARHP Annual Meeting
Rheumatic Immune Related Adverse Events of Checkpoint Therapy for Cancer: Case Series of a New Nosologic Entity
Cassandra Calabrese¹, Apostolos Kontzias¹, Vamsidhar Velcheti² and Leonard H. Calabrese¹, ¹Rheumatic & Immunologic Disease, Cleveland Clinic, Cleveland, OH, ²Hematology and Oncology, Cleveland Clinic, Cleveland, OH
Background/Purpose: The introduction of immunotherapy with biologic agents targeting immunologic checkpoints (i.e. CTLA4 and PD-1/PDL-1) have yielded impressive gains for cancer patients. These agents…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].